Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Solid Sales for Monoclonal Antibodies in Rheumatoid Arthritis Treatment May Prove Biologics Can Overcome the Patent Cliff

By BiotechDaily International staff writers
Posted on 25 Mar 2013
The market for monocloncal antibodies (mAbs) use in the treatment of rheumatoid arthritis (RA) since 2004 has experienced very significant growth, and it is on the threshold of entering a historically extraordinary scenario over the next six years, according to new market research.

According to healthcare market research company GBI Research (New York, NY, USA), eight mAbs are currently approved, half of which count among the top 10 best-selling drugs worldwide, collectively generating over USD 23 billion in sales in 2011. mAbs Remicade is also the blockbusting pharmaceutical product across the entire industry. The approaching patent cliff seems not likely to knock these popular drugs off their position, in a market that is slow to accept new products.

The first three mAbs to be approved to treat RA—Humira, Remicade, and Enbrel—have consistently dominated RA drug sales since their market entry, in spite of the approval of debatably more effective mAb products since then. GBI analyst Dominic Trewartha stated, “Physicians are likely to exercise great caution when prescribing biologics, in part due to their potentially serious side effects. Rheumatologists in general are also quite conservative in their treatment patterns, which could explain why Remicade, Humira and Enbrel are doing so well, being the first mAbs approved for RA. In contrast, biosimilars are less likely to be prescribed. For this reason, the growth of the global market is expected to continue in spite of the impending patent expiry of three of the four top-selling RA mAbs in the US.”

The RA mAbs market in the United States, Japan, Germany, France, the United Kingdom, Spain, and Italy is expected to grow from USD 11.5 billion in 2011 to USD 15.7 billion by 2018. Mr. He continued, “None of the potential market entrants appear to offer any significant improvements to existing medications, and thus will not dramatically affect the market size in the coming years, leaving Remicade, Humira, and Enbrel to maintain their top-selling RA mAbs status.”

The costs and problems tied to bringing biosimilars to the market is also expected to restrict the number of biosimilars and their impact on drug pricing for RA mAbs, estimated to be as low as 10%.

GBI Research is a provider of business intelligence reports, providing data and forecasts based on the insights of key industry experts with the latest emerging trends.

Related Links:

GBI Research



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Drug Discovery

view channel
Image: (Left) Neurons in brains from people with autism do not undergo normal pruning during childhood and adolescence. The images show representative neurons from unaffected brains (left) and brains from autistic patients (right); the spines on the neurons indicate the location of synapses (Photo courtesy of Guomei Tang, PhD and Mark S. Sonders, PhD, Columbia University Medical Center).

Autistic Youngsters Found to Have Too Many Brain Synapses

Autistic children and adolescents have been shown to have an excess of brain synapses, and this is due to a slowdown in the normal brain “trimming” process during development, according to new findings.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel

Important Immune Cell Regulators’ Response Identified

A new strategy could help accelerate laboratory research and the development of potential therapeutics, including vaccines. The technology may also be used to identify the genes that underlie tumor cell development. There are approximately 40,000 genes in each of the body’s cells, but functions for only approximately... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.